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Background: Estimating the prevalence of comorbidities and their associated costs in patients 
with diabetes is fundamental to optimizing health care management. This study assesses the 
prevalence and health care costs of comorbid conditions among patients with diabetes compared 
with patients without diabetes. Distinguishing potentially diabetes- and nondiabetes-related 
comorbidities in patients with diabetes, we also determined the most frequent chronic conditions 
and estimated their effect on costs across different health care settings in Switzerland.
Methods: Using health care claims data from 2011, we calculated the prevalence and aver-
age health care costs of comorbidities among patients with and without diabetes in inpatient 
and outpatient settings. Patients with diabetes and comorbid conditions were identified using 
pharmacy-based cost groups. Generalized linear models with negative binomial distribution 
were used to analyze the effect of comorbidities on health care costs.
Results: A total of 932,612 persons, including 50,751 patients with diabetes, were enrolled. 
The most frequent potentially diabetes- and nondiabetes-related comorbidities in patients 
older than 64 years were cardiovascular diseases (91%), rheumatologic conditions (55%), and 
hyperlipidemia (53%). The mean total health care costs for diabetes patients varied substantially 
by comorbidity status (US$3,203–$14,223). Patients with diabetes and more than two comor-
bidities incurred US$10,584 higher total costs than patients without comorbidity. Costs were 
significantly higher in patients with diabetes and comorbid cardiovascular disease (US$4,788), 
hyperlipidemia (US$2,163), hyperacidity disorders (US$8,753), and pain (US$8,324) compared 
with in those without the given disease.
Conclusion: Comorbidities in patients with diabetes are highly prevalent and have substantial 
consequences for medical expenditures. Interestingly, hyperacidity disorders and pain were the 
most costly conditions. Our findings highlight the importance of developing strategies that meet 
the needs of patients with diabetes and comorbidities. Integrated diabetes care such as used in 
the Chronic Care Model may represent a useful strategy.
Keywords: diabetes, comorbidity, chronic diseases, costs
Introduction
Diabetes is a highly prevalent chronic disease with a substantial medical and economic 
effect on health care systems worldwide.1,2 Because of diabetes, but also as a result of 
the various complications of diabetes, the burden is increasing tremendously. Diabetes 
is an established risk factor for comorbid chronic conditions such as cardiovascular dis-
eases, musculoskeletal diseases, and mental diseases.3–5 Diabetes comorbidities account 
for a substantial proportion of the medical expenditures in patients with diabetes.6–9 
Patients with diabetes and macrovascular and microvascular complications have total 
health care costs almost double those of patients without complications.10
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According to a US study from the American Diabetes 
Association, more than a quarter of health care expendi-
tures in five of eight comorbid diseases were attributed to 
diabetes.11 So far, most studies have focused only on a small 
selection of diabetes-related comorbidities and/or have lim-
ited their estimates to a single health care setting, mainly to 
inpatient hospital settings.9,12,13 Prior research showed that 
even conditions not directly related to diabetes, such as pain 
and depression, are more prevalent in diabetes, and thus 
emphasize the need to take into account both diabetes-related 
and nondiabetes-related comorbidities.3,14–16 Furthermore, 
Struijs and colleagues indicated in their study that the vari-
ous comorbid diseases have different effects on the type of 
health care use in patients with diabetes, and they stress the 
importance of considering multiple health care settings.14
To the best of our knowledge, there are no comprehen-
sive data on diabetes comorbid chronic conditions and their 
effect on health care costs in Switzerland. Because previous 
results may not be transferable to countries with different 
populations and health care delivery systems, it is important 
to evaluate the current situation of comorbidities in Swiss 
patients with diabetes. Therefore, the aim of our study was 
to provide a national overview of a wide range of (comorbid) 
chronic conditions in patients with diabetes compared with 
in patients without diabetes, as well as the associated health 
care costs across various health care settings for both patient 
groups. Distinguishing potentially diabetes-related and 
nondiabetes-related comorbidities in patients with diabetes, 
we also identified the most frequent chronic conditions and 
estimated their effect on costs.
Material and methods
Data source and study population
Patient-level health care claims data from the leading health 
insurance group (Helsana Group) in Switzerland were used. 
Switzerland is a federal parliamentary republic consisting 
of 26 cantons (states). It had a population of 8 million in 
2012. The prevalence of diabetes is about 5%.17 The Swiss 
health care system has mandatory coverage and is consumer-
driven; that is, consumers (about 70%), less employers 
(25%) or the government (about 5%), mainly pay health 
care costs through insurance premiums and out-of-pocket 
expenditures.18 In addition, the insurance coverage has a 
mandatory cost-sharing scheme consisting of co-payments 
and deductibles for all Swiss residents.  Co-payments are 
a charge of 10% of the annual health care costs that every 
insured person has to pay (limited to US dollars [US$]770/
Swiss Francs [CHF] 700 per year). Deductibles range from 
US$330–$2,750 (CHF 300–2,500) per year and can be 
chosen by the insured persons. The standard deductible is 
US$330 (CHF 300), but to reduce premiums, the insured 
persons can choose a higher deductible (US$550, $1,650, 
$2,200, or $2,750).
Helsana covers about 1.2 million Swiss residents with 
mandatory health insurance coverage in all 26 cantons. 
Available data comprise information on health care use, 
prescription drugs and laboratory tests, and the associated 
costs from all health care settings (eg, outpatient [primary and 
secondary care], inpatient, and nursing). These data achieve 
a high level of completeness, as the recorded insurance 
claims cover almost all health care and pharmacy invoices. 
We performed a cross-sectional study including all subjects 
who were at least 18 years old and were enrolled in 2011. 
According to national ethical and legal regulations, ethical 
approval was not needed for this study.
Identification of patients with diabetes 
and comorbidities
According to the Anatomical Therapeutic Chemical (ATC) 
classification system, all prescription drug items are coded 
and assigned to an ATC code in our database.19 Using the 
pharmacy-based cost group model, certain ATC codes can 
be assigned to different chronic diseases.20 In the absence of 
clinical diagnoses, this mapping approach provides a direct 
measure of treated chronic diseases and is commonly used 
as a reliable method to identify chronically ill patients in 
administrative databases.21–23 In addition, we used a modi-
fied version of the pharmacy-based cost group model, which 
included an updated and improved approach to the clas-
sification of medications. Patients were identified as having 
diabetes mellitus when they were prescribed at least one oral 
blood glucose-lowering drug (ATC code A10B), insulin (ATC 
code A10A), or another drug used in diabetes (ATC code 
A10X). We included a total of 22 chronic diseases based on 
the mapping approach for all chronic conditions performed 
by Huber and colleagues.24 In addition, we differentiated the 
chronic conditions (without diabetes) according to Struijs 
and colleagues and Du and colleagues between potentially 
diabetes-related and nondiabetes-related comorbidities 
among patients with diabetes.14,16 Diabetes-related comor-
bidities included cardiovascular diseases such as hyperten-
sion, hyperlipidemia, and glaucoma. Nondiabetes-related 
comorbidities included hyperacidity-related disorders, bone 
diseases (osteoporosis), cancer, dementia, epilepsy, gout/
hyperuricemia, HIV, intestinal inflammatory diseases, iron 
deficiency anemia, migraines, pain, Parkinson’s disease, 
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psychological disorders, respiratory illness, rheumatologic 
conditions, thyroid disorders, and tuberculosis.
estimation of prevalence and health  
care costs
We calculated the prevalence of each chronic disease by 
dividing the number of patients falling into the given disease 
group by the total number of persons included in the study 
for both patients with and patients without diabetes. Because 
chronic diseases are strongly associated with age, we report 
the prevalence for the age groups of 18–64 years and older 
than 64 years. Afterward, we compared the prevalence rates 
for both age groups by using chi-square tests. In a further 
step, we calculated the frequencies and proportions of the 
patient characteristics as well as the mean and median of total 
health care costs by comorbidity status among patients with 
and without diabetes. The comorbidity status was classified 
as no comorbidity, one comorbidity, two comorbidities, and 
more than two comorbidities among patients with diabetes. 
The (co)morbidity status was categorized with zero, one, 
two, or more than two chronic conditions among patients 
without diabetes. Differences between sex and age groups 
within the given comorbidity status groups were tested by 
chi-square tests. To compare the mean health care costs across 
the different comorbidity groups, we used Wilcoxon signed 
rank tests. Total health care costs were defined as the sum of 
payments made by the mandatory health insurance for out-
patient and inpatient care per patient/year. Outpatient costs 
included payments for office-based physician visits (primary 
care physicians, specialists), hospital ambulatory visits, para-
medical visits, nursing, laboratory tests, prescription drugs, 
and medical devices. Cost from the inpatient setting included 
payments for hospitalization, rehabilitation, nursing home, 
and emergency transport services, including all associated 
costs of medications, laboratory tests, and medical devices.
Multiple linear regression analyses were performed to 
determine the effect of comorbidities on health care costs 
among patients with and without diabetes. Given the skewed 
nature of the cost distribution, we used negative binomial 
regression models with a linear link function that provided 
absolute values in CHF as estimates. Afterward, the CHF 
values were converted to US$ at the 2011 exchange rate of 
1 CHF to 1.1 US$. Overall, we fitted four cost models for 
patients with diabetes and four models for patients without 
diabetes, according to their comorbidity status. The reference 
group in the respective models included patients without 
comorbidity among persons with diabetes and those without 
any chronic condition among persons without diabetes. In 
addition, we estimated regression models to assess the effect 
of the ten most frequent potentially diabetes- and nondiabe-
tes-related comorbidities on health care costs among patients 
with diabetes. All multivariate regression models included 
age, and sex, to correct for potential confounding. For the 
purposes of this study, a P-value of #0.05 was considered 
statistically significant. Analyses were performed using R, 
version 2.14.2 (R Foundation for Statistical Computing, 
Vienna, Austria).
Results
A total of 932,612 persons including 50,751 patients with 
diabetes were included in the study sample. We distinguished 
the characteristics of patients with and without diabetes, 
showing overall a higher percentage of men (54%) in the 
diabetes sample and a higher percentage of women in the 
nondiabetes sample (53%; results not shown).
Table 1 shows the population characteristics and the 
prevalence of comorbidities among patients with diabetes 
compared with those in patients without diabetes for the 
respective age groups. Approximately 60% of the sample 
with diabetes was older than 64 years, whereas almost 75% 
of the sample without diabetes were younger than 65 years. 
The mean number of comorbid chronic conditions was 3.3 
respectively 4.1 among patients with diabetes and signifi-
cantly higher compared with patients without diabetes (1.2 
respectively 3.0 conditions). The most frequent concurrent 
conditions in the population with diabetes were cardiovascu-
lar diseases including hypertension (18–64 years: 67%; older 
than 64 years: 91%), rheumatologic conditions (18–64 years: 
54%; older than 64 years: 55%), pain (18–64 years: 45%; 
older than 64 years: 50%), and hyperlipidemia (18–64 years: 
44%; older than 64 years: 53%).
Among patients without diabetes, the most commonly 
recorded comorbidities were cardiovascular diseases (older 
than 64 years: 63%), rheumatologic conditions (18–64 years: 
31%; older than 64 years: 47%), pain (18–64 years: 23%; 
older than 64 years: 39%), and psychological disorders 
(older than 64 years: 35%). The majority of comorbidities 
occurred significantly more frequently in patients with dia-
betes than in patients without diabetes in both age groups. 
Among persons without diabetes, the proportion of patients 
with each chronic condition is significantly higher in the 
older age group compared with in the younger group. With 
the exception of epilepsy, intestinal inflammatory diseases, 
and psychosis, comorbid conditions occurred significantly 
more often in older patients with diabetes than in younger 
patients with diabetes.
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The patient characteristics and health care costs cat-
egorized by diabetes and comorbidity status are presented 
in Tables 2 and 3. Of the 50,751 patients with diabetes, 
almost all persons had at least one concurrent condition 
(96%). Furthermore, there were higher proportions of men 
in the diabetes sample. Among the patients without diabe-
tes (n=881,861), a total of 530,320 (60%) had at least one 
chronic condition other than diabetes, with a higher percent-
age of women. The majority of the persons with one or two 
chronic conditions were younger than 64 years old; comor-
bid patients with more than two conditions were equally 
represented in both age groups. The mean total health care 
costs in 2011 varied substantially between the comorbidity 
status in patients with diabetes, ranging from US$3,203 in 
patients with only diabetes to US$14,223 in patients with 
more than two concurrent conditions. Annual costs of both 
the outpatient setting (US$1,403 versus $5,577) and the 
inpatient setting (US$553 versus $4,764), as well as the cost 
of prescription drugs (US$857 versus $3,726), were highest 
in patients with diabetes and at least three comorbidities. 
Overall, the total health care costs are significantly higher in 
patients with diabetes and comorbidities than in patients with 
diabetes only. Among persons without diabetes, the mean 
total health care costs were highest in multimorbid patients 
with more than two chronic conditions (US$10,429 versus 
$928). The costs varied across the different health care set-
tings, from US$4,535 in the outpatient setting and US$3,488 
in the inpatient setting for patients without diabetes and 
with at least three chronic diseases. After splitting the cost 
estimates into two age groups (18–64 years and older than 
64 years), we could still observe higher average health care 
costs in all categories, with the exception of older patients 
Table 1 Population characteristics and prevalence of comorbidities among patients with, compared with patients without, diabetes
Population characteristics Diabetes sample (n=50,751) Nondiabetes sample (n=881,861)
18–64 years, % .64 years, % P-value 18–64 years, % .64 years, % P-value
 Total 37.8 62.2 74.3 25.7
Sex ,0.001† ,0.001†
 Male 59.1 51.4 49.7 39.6
 Female 40.9 48.6 50.3 60.4
 Mean number of chronic  
conditions (standard deviation)
3.3 (2.0) 4.1 (1.9) ,0.001‡ 1.2 (1.6) 3.0 (2.1) ,0.001‡
Comorbidities¶
 hyperacidity-related disorders 34.9*** 39.4*** ,0.001† 14.4 30.8 ,0.001†
 Bone diseases (osteoporosis) 1.4*** 4.2*** ,0.001† 0.7 7.0 ,0.001†
 cancer 1.7*** 3.1 ,0.001† 0.8 2.9 ,0.001†
  cardiovascular diseases  
(including hypertension)
67.1*** 91.0*** ,0.001† 13.2 62.8 ,0.001†
 Dementia 1.4*** 5.1 ,0.001† 0.5 5.0 ,0.001†
 epilepsy 6.5*** 6.6*** 0.467† 2.2 4.2 ,0.001†
 glaucoma 3.9*** 13.1*** ,0.001† 0.9 10.2 ,0.001†
 gout, hyperuricemia 4.4*** 9.3*** ,0.001† 0.6 3.7 ,0.001†
 hiV 0.3 0.1 ,0.001† 0.3 0.01 ,0.001†
 hyperlipidemia 43.8*** 53.4*** ,0.001† 4.8 25.7 ,0.001†
 Intestinal inflammatory diseases 0.6*** 0.7 0.773† 0.4 0.7 ,0.001†
 Iron deficiency anemia 5.7*** 6.4*** ,0.001† 4.1 3.4 ,0.001†
 Migraine 1.2* 0.3*** ,0.001† 1.5 0.6 ,0.001†
 Pain 45.3*** 49.8*** ,0.001† 22.6 39.0 ,0.001†
 Parkinson’s disease 1.4*** 3.7*** ,0.001† 0.4 3.0 ,0.001†
  Psychological disorders  
(sleep disorder, depression)
32.3*** 41.0*** ,0.001† 15.0 35.4 ,0.001†
 Psychoses 6.1*** 6.3*** 0.505† 2.4 4.9 ,0.001†
  respiratory illness (asthma, chronic  
obstructive pulmonary disease)
11.8*** 13.1*** ,0.001† 5.9 10.5 ,0.001†
 rheumatologic conditions 54.3*** 55.0*** 0.107† 30.8 47.1 ,0.001†
 Thyroid disorders 7.2*** 9.3*** ,0.001† 2.3 7.0 ,0.001†
 Tuberculosis 0.2*** 0.1 0.026† 0.1 0.1 ,0.001†
Notes: †chi-square test comparing age groups within each sample with/without diabetes; ‡Wilcoxon test comparing age groups in sample with/without diabetes. ¶chi-square 
test comparing sample of same age groups across sample with diabetes and without diabetes, respectively; *P-value, #0.05; ***P-value, #0.001.
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in the nondiabetes-only compared with the diabetes-only 
group (Figure 1).
Table 4 presents the results of the multivariate regression 
models estimating the effect of comorbidities on health care 
costs. After adjusting for sex and age, a substantial gradient 
between the number of comorbidities and health care costs in 
all health care settings could be observed among patients with 
and without diabetes. The total costs were almost US$10,600 
higher in patients with diabetes (coefficient, US$10,584; 
95% confidence interval [CI], US$10,329–$10,834) and 
about US$8,300 higher in those without diabetes (coefficient, 
US$8,293; 95% CI, US$8,199–$8,389) with at least three 
chronic conditions compared with persons without comorbid-
ity. The costs from both outpatient and inpatient settings, from 
prescription drugs and laboratory tests, each significantly 
increased with the number of concurrent (comorbid) chronic 
conditions in both samples.
The effect of the ten most common diabetes-related 
comorbidities on the health care costs is shown in Tables 5 and 
6. All comorbidities caused a significant increase in health 
care costs in all considered settings. Regarding the diabetes-
related comorbidities of cardiovascular diseases and hyper-
lipidemia, the total health care costs were about US$4,800 
(coeff icient, US$4,788; 95% CI, US$4,576–$5,000) 
and almost US$2,200 (coefficient, US$2,163; 95% CI, 
US$1,964–$2,362) higher in these comorbid patients than 
in diabetes patients without the given chronic conditions. 
Furthermore, patients with diabetes and each comorbid pain-, 
psychological-, or  hyperacidity-related disorder incurred 
US$8,000, on average, in higher total health care costs com-
pared with the given reference group.
Discussion
In this study, we provide the first national overview of the 
diabetes comorbidity status in Switzerland, evaluating the 
prevalence and costs of potentially diabetes- and nondiabetes-
related comorbid conditions in inpatient and outpatient health 
care settings among patients with diabetes.
First, our study showed a higher proportion of adults older 
than 64 years among patients with diabetes than those without 
diabetes. This result suggests that our sample included a high 
number of patients with type 2 diabetes, which is typically 
associated with older ages.25 Furthermore, we identified car-
diovascular diseases including hypertension, rheumatologic 
conditions, hyperlipidemia, and pain as the most common 
concurrent chronic conditions in patients with diabetes. These 
findings are in line with previous studies from Germany 
showing highest rates of hypertension, hyperlipidemia, and 
musculoskeletal diseases in patients with diabetes.16 From 
previous reports, cardiovascular diseases and hyperlipidemia 
are well known to be strongly associated with diabetes, even 
after adjustment for other risk factors of comorbidity such as 
age, sex, glycemia, and smoking.4 In addition, nondiabetes-
related comorbidities such as musculoskeletal and rheuma-
tologic conditions could be observed as a concurrent chronic 
condition in a recent study.26 Longstanding diabetes may be 
harmful for knee and hip joints and includes a doubled risk 
for severe osteoarthritis needing arthroplasty.26 Overall, and 
0 4,000 8,000
Mean costs (US$)
12,000 16,000
>64 years
18–64 years
Diabetes only
Diabetes with 1 CC
Diabetes with 2 CC
Diabetes with >2 CC
Nondiabetes only
Nondiabetes with 1 CC
Nondiabetes with 2 CC
Nondiabetes with >2 CC*
*CC: chronic condition(s)
Figure 1 Mean total health care costs in patients with and without diabetes by comorbidity status.
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in line with numerous previous studies, our analyses showed 
that the majority of the comorbid chronic conditions occurred 
more frequently in patients with diabetes than in patients 
without diabetes.27–29
Furthermore, this study provides a description of the 
distribution of the total health care costs among patients with 
diabetes distinguished by with and without comorbidity. The 
costs varied substantially between the different groups cat-
egorized by comorbidity status. On average, the total annual 
costs in 2011 for diabetes care were about US$3,000 (€2,000; 
exchange rate of US$1 to €0.7 in 2011) in patients with dia-
betes only and about US$14,000 (€10,000) in patients with 
more than two concurrent conditions across all age groups. 
Overall, the total health care costs were significantly higher 
in patients with diabetes and comorbidities than in patients 
with diabetes only. Furthermore, the total health care costs 
were higher in patients with diabetes than in patients without 
diabetes in all comorbidity categories. However, we could 
observe one exception when we split the cost estimates into 
two age groups. Interestingly, there were higher average costs 
in the nondiabetes-only compared with the diabetes-only 
group among older patients. One explanation could be that 
in this age group, the distribution of costs was extremely 
skewed, with a mean of US$4,200 (€3,000) and a median 
of US$180 (€130). Because most of the previous studies 
included only a few major diabetes-related comorbidities, 
comparability of our direct average costs and those from 
other studies is limited. However, overall rising costs were 
related to an increased number of coexisting chronic diseases. 
For example, a study from Italy reported costs of €1,040 
in patients with no major complications and of €3,141 in 
patients with two or more complications.13
Turning to the potential effect of comorbidities on health 
care expenditures, our results demonstrated that both poten-
tially diabetes-related and nondiabetes-related comorbid 
conditions in patients with diabetes have a substantial effect 
on medical expenditures in health care systems. The increas-
ing number of comorbid chronic conditions led to increasing 
annual medical expenditures, especially in total health care 
costs, outpatient costs, and prescription drug costs. Consistent 
with findings from previous studies, our analyses showed 
that suffering from at least two comorbidities has the highest 
effect on health care costs among patients with diabetes.12,13 
Further studies also reported that concurrent conditions 
cause an increasing demand for total health care, a greater 
length of hospital stay, and higher total hospital charges, 
and that they lead to increasing mortality.12,14,30  Considering 
the ten most frequent concurrent chronic conditions, we 
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observed varying effects, depending on the category of 
comorbidity. Nondiabetes-related comorbidities such as pain, 
hyperacidity-related disorders, and psychological disorders 
showed the strongest effect (up to a doubling) on total health 
care costs among patients with diabetes. This finding stresses 
the importance not only of directly diabetes-related comor-
bidities but also of nondiabetes-related comorbidities such 
as hyperacidity-related disorders. Wang and colleagues, for 
example, reported that about 40% of patients with diabetes 
suffer from gastroesophageal reflux disease.31 Moreover, the 
authors showed that patients with diabetes and neuropathy 
were more likely to suffer from this disease than patients 
without neuropathy. In addition, our results are in line with 
previous studies reporting a strong association between 
diabetes and pain, as well as psychological disorders inclu-
sive of depression.32,33 Egede and colleagues found a strong 
association between depression in persons with diabetes and 
increased health care costs, regardless of age, sex, and other 
comorbidities.33
Interestingly, we could observe a greater effect of 
several comorbidities, such as cardiovascular disease or 
hyperlipidemia, on outpatient costs than on inpatient costs 
in patients with diabetes. One explanation may be that 
patients with diabetes and comorbidities are more likely 
to seek outpatient than inpatient care.34 Patients who suf-
fer from chronic diseases, in particular, need continuous 
treatment and management in primary and outpatient 
specialist care.35,36 Our findings highlight the importance 
of continuing and strengthening diabetes management, 
addressing the needs for patients with multimorbidity in 
primary care. Beyond general guidelines for the care of 
patients, effective diabetes management requires an inte-
grated, more holistic, and patient-centered concept.37 The 
Chronic Care Model (CCM) provides a useful approach 
for an improved and efficient management of multimor-
bid patients, mainly within primary care. The CCM was 
developed by Wagner and colleagues and represents an 
evidence-based conceptual framework for the treatment of 
chronically ill persons, including a comprehensive, multi-
faceted approach for patients with chronic diseases across 
the entire health care system.36,38,39 The six elements of the 
CCM include patient self-management support, evidence-
based guidelines for decision support, delivery system 
design (eg, multidisciplinary teams), clinical information 
systems (eg, reminder systems), health care organization 
(eg, support of the leaders), and community resources. 
There is strong evidence that supports the CCM’s effective-
ness, showing an improvement in patient care and health 
outcomes such as glycated hemoglobin values and heart 
disease risk factors.40–42
This study has several strengths and limitations. One of 
the main strengths is that our study is the first that provides 
a national overview of a large number of both potentially 
diabetes- and nondiabetes-related comorbidities as well as 
their effect on health care costs across various health care 
settings in Switzerland. Furthermore, this study is based 
on a very comprehensive administrative claims database 
that encompasses a large population across Switzerland. 
Administrative data are a reliable, large-sized, and practice-
based data source that provides sufficient information on 
morbidity and medical cost of patients. Moreover, these 
databases are very valuable when disease register or health 
survey studies are lacking.
However, this study also has several limitations. First, 
costs may be underestimated because in approximately 3% 
of all claims, invoices were not reimbursed by the health 
insurer and were paid out of pocket by the patient. Second, 
as medical diagnoses are not available in our data, we used 
drug-based diagnoses as a proxy for clinical  diagnoses. 
Thus, comorbidities in patients with diabetes may be biased 
because not all ATC codes could be directly and uniquely 
assigned to the treatment of a certain disease. Furthermore, 
as population-based clinical parameters (eg, International 
Statistical Classification of Diseases and Related Health 
Problems, Tenth Revision) are very scarce in  Switzerland, we 
could not compare our model performance with a diagnosed-
based model. However, numerous studies could show that 
prescription data are a valid measure for prevalence of dia-
betes and other chronic diseases.20–23 For example, Cossman 
and colleagues showed that prescribed drug rates are a useful 
proxy for “disease-specific diagnoses prevalence.”21 In addi-
tion, Chini and coworkers revealed drug data as a reliable 
source for prevalence estimates of chronic diseases.23 In 
particular, the use of prescription for antidiabetic drugs 
could be used for an accurate identification of diabetics 
across large populations.43,44 Third, several comorbidities, 
such as cardiovascular diseases including hypertension, 
were broadly defined, and further common complications in 
diabetes (eg, chronic kidney disease) could not be analyzed 
at all in the study because not every chronic disease allows 
an unambiguous identification by prescription drug items 
according to the used pharmacy-based cost group model. A 
fourth limitation of the study is that our estimates are not 
entirely representative of the general population. The sample 
included a slightly higher proportion of elderly persons than 
in the entire Swiss population. A detailed  comparison of 
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the proportions of the population characteristics between 
our study sample and the entire Swiss population has been 
described elsewhere.17
In conclusion, comorbidities in patients with diabetes 
are highly prevalent and have substantial consequences for 
medical expenditures. Interestingly, hyperacidity disorders 
and pain were the most costly conditions. Our findings 
highlight the importance of developing strategies that 
meet the needs of patients with diabetes and  comorbidities. 
 Furthermore, our study strengthens the demand for inte-
grated diabetes care programs, which include multifaceted 
and patient-centered elements. Applying general principles 
of the CCM may contribute to more effective diabetes 
care in the context of the growing proportion of multimor-
bidity in the population.
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